---
figid: PMC6753603__f1000research-7-14236-g0001
figlink: /pmc/articles/PMC6753603/figure/f2/
number: F2
caption: The pathways can be activated by receptor tyrosine kinases (RTKs) being activated
  by growth factors or by overexpression of the receptor. Constitutive activation
  of the signaling pathways can be caused by mutations along the pathway, such as
  BRAF, RAS, PI3K, AKT, or mammalian target of rapamycin (mTOR), mutations in tumor
  suppressor genes, such as neurofibromin 1 (NF1) or phosphatase and tensin homolog
  (PTEN) mutations, or fusion RTKs, such as those in RET, neurotropic tropomyosin
  receptor kinase (NTRK), or anaplastic lymphoma kinase (ALK). Drugs that can inhibit
  at critical points in the pathway are listed in grey boxes. FGFR, fibroblast growth
  factor receptor; TSC1, tuberous sclerosis complex 1; TSC2, tuberous sclerosis complex
  2; VEGFR, vascular endothelial growth factor receptor.
pmcid: PMC6753603
papertitle: Recent advances and emerging therapies in anaplastic thyroid carcinoma.
reftext: Maria E. Cabanillas, et al. F1000Res. 2018;7:F1000 Faculty Rev-87.
pmc_ranked_result_index: '151199'
pathway_score: 0.9506511
filename: f1000research-7-14236-g0001.jpg
figtitle: Schematic overview of the two most common pathways with genetic alterations
  in thyroid cancerâ€”mitogen-activated protein kinase (MAPK) and phosphatidylinositide
  3-kinase (PI3K) pathways
year: '2018'
organisms:
- Homo sapiens
ndex: 92567162-deef-11ea-99da-0ac135e8bacf
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC6753603__f1000research-7-14236-g0001.html
  '@type': Dataset
  description: The pathways can be activated by receptor tyrosine kinases (RTKs) being
    activated by growth factors or by overexpression of the receptor. Constitutive
    activation of the signaling pathways can be caused by mutations along the pathway,
    such as BRAF, RAS, PI3K, AKT, or mammalian target of rapamycin (mTOR), mutations
    in tumor suppressor genes, such as neurofibromin 1 (NF1) or phosphatase and tensin
    homolog (PTEN) mutations, or fusion RTKs, such as those in RET, neurotropic tropomyosin
    receptor kinase (NTRK), or anaplastic lymphoma kinase (ALK). Drugs that can inhibit
    at critical points in the pathway are listed in grey boxes. FGFR, fibroblast growth
    factor receptor; TSC1, tuberous sclerosis complex 1; TSC2, tuberous sclerosis
    complex 2; VEGFR, vascular endothelial growth factor receptor.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - PIK3CG
  - ARAF
  - PIK3R3
  - PTEN
  - PIK3CD
  - NRAS
  - BRAF
  - HRAS
  - KRAS
  - FLT1
  - KDR
  - RET
  - MAP2K1
  - RAF1
  - AKT3
  - AKT2
  - AKT1
  - ALK
  - TSC1
  - TSC2
  - FLT4
  - FGFR1
  - FGFR3
  - MAP2K2
  - NTRK1
  - MTOR
  - NF1
  - NTRK3
  - PIK3R4
  - NTRK2
  - PIK3R5
  - PIK3R6
  - PIK3CA
  - PIK3CB
  - FGFR2
  - MAPK3
  - MAPK1
  - Tyrosine
  - lenvatinib
  - vemurafenib
  - dabrafenib
  - PLX8394
  - crizotinib
  - ceritinib
  - cobimetinib
  - trametinib
  - selumetinib
  - RO5126766
  - everolimus
  - temsirolimus
  - MLN0128
  - Cancer
  - Cardiomyopathy
  - Lung cancer
  - Noonan syndrome
genes:
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CG
  entrez: '5294'
- word: RAF
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: ARAF
  entrez: '369'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R3
  entrez: '8503'
- word: PTEN
  symbol: PTEN
  source: hgnc_symbol
  hgnc_symbol: PTEN
  entrez: '5728'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CD
  entrez: '5293'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: NRAS
  entrez: '4893'
- word: RAF
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: BRAF
  entrez: '673'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: HRAS
  entrez: '3265'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: KRAS
  entrez: '3845'
- word: VEGFR1-3,
  symbol: VEGFR1
  source: hgnc_alias_symbol
  hgnc_symbol: FLT1
  entrez: '2321'
- word: VEGFR1-3,
  symbol: VEGFR2
  source: hgnc_alias_symbol
  hgnc_symbol: KDR
  entrez: '3791'
- word: VEGFR1-3,RET,FGFR1-3
  symbol: RET
  source: hgnc_symbol
  hgnc_symbol: RET
  entrez: '5979'
- word: MEK
  symbol: MEK
  source: bioentities_symbol
  hgnc_symbol: MAP2K1
  entrez: '5604'
- word: RAF
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: RAF1
  entrez: '5894'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT3
  entrez: '10000'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT2
  entrez: '208'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT1
  entrez: '207'
- word: ALK
  symbol: ALK
  source: hgnc_symbol
  hgnc_symbol: ALK
  entrez: '238'
- word: BRAF
  symbol: BRAF
  source: hgnc_symbol
  hgnc_symbol: BRAF
  entrez: '673'
- word: TSC1/2
  symbol: TSC1
  source: hgnc_symbol
  hgnc_symbol: TSC1
  entrez: '7248'
- word: TSC1/2
  symbol: TSC2
  source: hgnc_symbol
  hgnc_symbol: TSC2
  entrez: '7249'
- word: VEGFR1-3,
  symbol: VEGFR3
  source: hgnc_alias_symbol
  hgnc_symbol: FLT4
  entrez: '2324'
- word: FGFR1-3
  symbol: FGFR1
  source: hgnc_symbol
  hgnc_symbol: FGFR1
  entrez: '2260'
- word: FGFR1-3
  symbol: FGFR3
  source: hgnc_symbol
  hgnc_symbol: FGFR3
  entrez: '2261'
- word: MEK
  symbol: MEK
  source: bioentities_symbol
  hgnc_symbol: MAP2K2
  entrez: '5605'
- word: NTRK
  symbol: NTRK
  source: bioentities_symbol
  hgnc_symbol: NTRK1
  entrez: '4914'
- word: MTOR
  symbol: MTOR
  source: hgnc_symbol
  hgnc_symbol: MTOR
  entrez: '2475'
- word: NF1
  symbol: NF1
  source: hgnc_symbol
  hgnc_symbol: NF1
  entrez: '4763'
- word: NTRK
  symbol: NTRK
  source: bioentities_symbol
  hgnc_symbol: NTRK3
  entrez: '4916'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R4
  entrez: '30849'
- word: NTRK
  symbol: NTRK
  source: bioentities_symbol
  hgnc_symbol: NTRK2
  entrez: '4915'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R5
  entrez: '23533'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R6
  entrez: '146850'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CA
  entrez: '5290'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CB
  entrez: '5291'
- word: FGFR1-3
  symbol: FGFR2
  source: hgnc_symbol
  hgnc_symbol: FGFR2
  entrez: '2263'
- word: ERK
  symbol: ERK
  source: bioentities_symbol
  hgnc_symbol: MAPK3
  entrez: '5595'
- word: ERK
  symbol: ERK
  source: bioentities_symbol
  hgnc_symbol: MAPK1
  entrez: '5594'
chemicals:
- word: Tyrosine
  source: ''
  identifier: ''
- word: lenvatinib
  source: MESH
  identifier: C531958
- word: vemurafenib
  source: MESH
  identifier: C551177
- word: dabrafenib
  source: MESH
  identifier: C561627
- word: PLX8394
  source: MESH
  identifier: C581574
- word: crizotinib
  source: MESH
  identifier: C551994
- word: ceritinib
  source: MESH
  identifier: C586847
- word: cobimetinib
  source: MESH
  identifier: C574276
- word: trametinib
  source: MESH
  identifier: C560077
- word: selumetinib
  source: MESH
  identifier: C517975
- word: RO5126766
  source: MESH
  identifier: C577924
- word: everolimus
  source: MESH
  identifier: C107135
- word: temsirolimus
  source: MESH
  identifier: C401859
- word: MLN0128
  source: MESH
  identifier: C572449
diseases:
- word: Cancer
  source: ''
  identifier: ''
- word: Cardiomyopathy
  source: ''
  identifier: ''
- word: Lung cancer
  source: ''
  identifier: ''
- word: Noonan syndrome
  source: ''
  identifier: ''
figid_alias: PMC6753603__F2
redirect_from: /figures/PMC6753603__F2
figtype: Figure
---
